ANIMAL CELL;
ANIMAL EXPERIMENT;
AREA UNDER THE CURVE;
ARTICLE;
CONTROLLED STUDY;
DRUG ABSORPTION;
DRUG BILE LEVEL;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG FECES LEVEL;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG SELECTIVITY;
DRUG TRANSFORMATION;
EXPERIMENTAL DOG;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
IN VIVO STUDY;
LIVER CELL;
MALE;
MAXIMUM PLASMA CONCENTRATION;
NONHUMAN;
QUALITATIVE ANALYSIS;
RADIOACTIVITY;
RAT;
SPECIES DIFFERENCE;
TANDEM MASS SPECTROMETRY;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TOXICITY TESTING;
AGONISTS;
ANIMAL;
BIOAVAILABILITY;
BLOOD;
CHEMICAL STRUCTURE;
CHEMISTRY;
DOG;
METABOLISM;
ORAL DRUG ADMINISTRATION;
SPRAGUE DAWLEY RAT;
ADMINISTRATION, ORAL;
ANIMALS;
BIOLOGICAL AVAILABILITY;
CARBON RADIOISOTOPES;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
DOGS;
HEPATOCYTES;
HUMANS;
MALE;
MOLECULAR STRUCTURE;
PYRIDONES;
RATS;
RATS, SPRAGUE-DAWLEY;
RECEPTOR, CANNABINOID, CB2;
SPECIES SPECIFICITY;
TANDEM MASS SPECTROMETRY;
Structure-Activity relationships for degradation reaction of 1-beta-o-Acyl glucuronides: Kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions
Baba A, Yoshioka T. (2009). Structure-Activity relationships for degradation reaction of 1-beta-o-Acyl glucuronides: kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions. Chem Res Toxicol 22:158-72.
Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance
Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35: 293-301.
(M3 R2): Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Available from [last accessed 19 Nov 2012]
International Conference on Harmonization. (2009) M3(R2): Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Available from: http://private.ich. org/cache/compo/502-272-1.html [last accessed 19 Nov 2012].
Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies
Isin EM, Elmore CS, Nilsson GN, et al. (2012). Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol 25:532-42.
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure
Jolivette LJ, Ward KW. (2005). Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J Pharm Sci 94: 1467-83.
Recent advances in the development of selective CB 2) agonists as promising anti-inflammatory agents
Leleu-Chavain N, Body-Malapel M, Spencer J, et al. (2012). Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents. Curr Med Chem 19:3457-74.
Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry
Mailleux P, Vanderhaeghen JJ. (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655-68.
Effect of phenobarbital and other model inducers on cytochrome P450 isoenzymes in primary culture of dog hepatocytes
Nishibe Y, Hirata M. (1993). Effect of phenobarbital and other model inducers on cytochrome P450 isoenzymes in primary culture of dog hepatocytes. Xenobiotica 23:681-92.
Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent
Odan M, Ishizuka N, Hiramatsu Y, et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg Med Chem Lett 22:2803-6.
Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: Why, when, and how?
Penner N, Xu L, Parakash C. (2012). Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513-31.
U.S. FDA, United States Food and Drug Administration Guidance for Industry, Safety testing of drug metabolites, February 2008. Available from: http://www.fda.gov/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ ucm065014.htm [last accessed 19 Nov 2012].
Clinical consequences of the biphasic elimination kinetics for the diuretic effect of frosemide and its acyl glucuronide in humans
Vree TB, van der Ven AJ. (1999). Clinical consequences of the biphasic elimination kinetics for the diuretic effect of frosemide and its acyl glucuronide in humans. J Pharm Pharmacol 51:239-48.
A holistic strategy for characterizing the safety of metabolites through drug discovery and development
Walker D, Brady J, Dalvie D, et al. (2009). A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22:1653-62.
